European Due Diligence Summit for Life Sciences -

European Due Diligence Summit for Life Sciences
26–27 February 2018
London, United Kingdom

Conduct efficient and effective due diligence on licensing deals, acquisitions, and strategic alliances

European Due Diligence Summit for Life Sciences – European Due Diligence Summit for Life Sciences

Recent years have shown a rise in development across the generic and biosimilar industries, as many blockbuster products near the end of their patents. The need to expand the reach of R&D programmes has driven major new investments in co-development, strategic alliances, licensing and acquisitions, with big pharmaceutical companies scrambling to maintain their strongholds in specific therapeutic areas. This has increased the need for a robust due diligence process across all functions, as companies look to external targets as a means of supplementing pipelines and bolstering their product portfolios.

With the rising costs of drug and device reviews and the uncertainty of FDA approvals, the prospect of developing a new product from discovery onward has become a highly risky endeavour. Therefore, conducting strategic due diligence to identify and integrate potential targets at a stage of assured success, though costly, can often be an efficient approach to supplement organic business development.

Over the last four years, ExL Events’ US-based conference has provided due diligence professionals with a platform to explore innovative models and deal structures for collaborating with strategic partners, and discussed valuable strategies for conducting efficient and effective due diligence. Join your peers at the inaugural European Due Diligence Summit for Life Sciences for the opportunity to network and engage with some of the industry’s leading experts.

Top Five Reasons to Attend

  1. Explore best practices for companies of all sizes looking to acquire or in-license a product
  2. Understand how to conduct a comprehensive intellectual property due diligence investigation, and how it can alter the strategy for your deal
  3. Learn how to evaluate and effectively manage strategic alliances through case studies from industry leaders
  4. Assess the regulatory and compliance standards of a target and how gaps can lead to unforeseen financial burdens
  5. Gain valuable insight on the impact company culture can have on the success of integrating the workforce post-merger or acquisition

Who Should Attend

This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:

  • Due Diligence
  • Business Development
  • Strategic Alliance/Alliance Management
  • Mergers and Acquisitions
  • Licensing
  • Intellectual Property and Patent Counsel
  • Search and Evaluation
  • Portfolio Management
  • Scientific Assessment
  • General Counsel/Corporate Counsel
  • Legal and Regulatory Compliance
  • Regulatory Affairs
  • Research and Development
  • Clinical Medicine
  • Clinical Operations
  • Lifecycle Management

This conference is also of interest to:

  • Investment Banks
  • Private Equity Firms
  • Venture Capitalists
  • Data Room Providers
  • Due Diligence Consultants
  • Law Firms
  • Clinical Affairs and CRO Partners
  • Regulatory Affairs and Compliance Partners
Startdate: 2018-02-26
End Date 2018-02-27

Description: The European Due Diligence Summit for Life Sciences is the leading cross-functional life science event focused on the needs of due diligence professionals. This conference will provide attendees with the strategies & insight they need to conduct a thorough due diligence in order to ensure a profitable investment in a new product, portfolio or company.
Performer: ExL Events
Address : European Due Diligence Summit for Life Sciences

live chat software